Sermorelin Side Effects: Safety Signals and Warnings
Sermorelin safety concerns are compound-specific. The main listed side effects are Injection site reactions (redness, swelling), Facial flushing, and Headache. The main warning signals are Previously FDA-approved but discontinued (for commercial, not safety reasons), May not be effective in severe pituitary damage, and Monitor for excessive GH/IGF-1 elevation.
Direct Answer
Sermorelin has legitimate historical approval and human GH-stimulation data, but no currently marketed FDA-approved product and no validated anti-aging indication. Tesamorelin has the stronger current regulatory record; CJC-1295 is not an approved substitute.
- Evidence grade
- Level B
- Research status
- Historical FDA Approval
- Category
- Growth Hormone
- Evidence context
- Historical pediatric GH-deficiency evidence and GHRH-axis research
Reported Side Effects
- Injection site reactions (redness, swelling)
- Facial flushing
- Headache
- Dizziness
- Sleepiness
Warnings
- Previously FDA-approved but discontinued (for commercial, not safety reasons)
- May not be effective in severe pituitary damage
- Monitor for excessive GH/IGF-1 elevation
- Not for use with active malignancy
Known or Plausible Interactions
- Exogenous GH (use one or the other)
- Glucocorticoids (may blunt response)
- Thyroid hormones (hypothyroidism may reduce response)
- Other GH secretagogues (synergistic)
Regulatory Context
Geref previously held FDA approval for pediatric growth hormone deficiency and diagnostic use. Drugs@FDA lists the sermorelin products as discontinued and not withdrawn for safety or effectiveness reasons. Compounded sermorelin products are not FDA-approved and are not reviewed like an approved drug before marketing.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Historical FDA Approval |
| Best supported outcomes | Growth Hormone Stimulation (Level B), Body Composition (Adults) (Level C), and Sleep Quality (Level C) |
| Primary citation count | 2 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Sermorelin?
Sermorelin safety concerns are compound-specific. The main listed side effects are Injection site reactions (redness, swelling), Facial flushing, and Headache. The main warning signals are Previously FDA-approved but discontinued (for commercial, not safety reasons), May not be effective in severe pituitary damage, and Monitor for excessive GH/IGF-1 elevation.
What is the evidence level for Sermorelin?
Sermorelin is rated Level B. Its current research status is Historical FDA Approval.
What is Sermorelin best known for?
Historical pediatric GH-deficiency evidence and GHRH-axis research.
Where can I read the full Sermorelin evidence review?
The full evidence review is available at https://examinepeptides.com/library/sermorelin.
Related Guides
How to Cite This Page
ExaminePeptides. "Sermorelin Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/sermorelin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.